# Praxis Precision Medicines (stock symbol: PRAX) Logo in transparent PNG and SVG formats

## Praxis Precision Medicines Logo large

### Praxis Precision Medicines Logo large Download PNG (45.29 KB)

![Praxis Precision Medicines Logo large Download PNG (45.29 KB)](/img/orig/PRAX_BIG-006dae1a.png)

### Praxis Precision Medicines Logo large Download SVG (3.97 KB)

![Praxis Precision Medicines Logo large Download SVG (3.97 KB)](/img/orig/PRAX_BIG-8a6f376d.svg)

## Praxis Precision Medicines Logo icon format

### Praxis Precision Medicines Logo icon format Download PNG (73.85 KB)

![Praxis Precision Medicines Logo icon format Download PNG (73.85 KB)](/img/orig/PRAX-630d287b.png)

### Praxis Precision Medicines Logo icon format Download SVG (1.34 KB)

![Praxis Precision Medicines Logo icon format Download SVG (1.34 KB)](/img/orig/PRAX-d165d819.svg)

## Praxis Precision Medicines Logo large for dark backgrounds

### Praxis Precision Medicines Logo large for dark backgrounds Download PNG (46.13 KB)

![Praxis Precision Medicines Logo large for dark backgrounds Download PNG (46.13 KB)](/img/orig/PRAX_BIG.D-3dca5b2e.png)

### Praxis Precision Medicines Logo large for dark backgrounds Download SVG (3.97 KB)

![Praxis Precision Medicines Logo large for dark backgrounds Download SVG (3.97 KB)](/img/orig/PRAX_BIG.D-b2c67a8a.svg)

## About Praxis Precision Medicines

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.

1. Website domain: praxismedicines.com
2. Employees: 109
3. Marketcap: $54.48 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
